UCB S.A.
UCBJF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$44.28B
Close$
$263.62
13.8% downside
Current Fair Value
13.8% downsideOvervalued by 13.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $44.28 Billion |
|---|---|
| Enterprise Value | - |
| Annual dividend | $1.70 |
| Dividend yield | 0.71% |
| Earnings per Share | $8.2 |
| Beta | 0.2 |
| Outstanding Shares | 190,597,757 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 17.62 |
|---|---|
| PEG | 12.72 |
| Price to Sales | 3.82 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$5.81
Consensus analyst estimateRevenue Estimate
$4.64 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$7.92
Consensus analyst estimateRevenue Estimate
$5.23 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About UCB S.A.
9,000 employees
CEO: Jean-Christophe Tellier
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized p...